Supply issue: testosterone cipionate Inj 100 mg per ml, 10 ml vial (Depo-Testosterone)

Kia ora

We are writing to inform you of a supply issue.

Key messages

• The supplier Pfizer has informed us that Depo-Testosterone will be in short supply from late-October to mid-December 2025.

• Pfizer has been unable to source an alternative bioequivalent product.

• Please consider not starting any new patients on Depo-Testosterone for the supply issue period

• Clinical advice has told us - prescribers may wish to consider alternative funded testosterone products, such as Reandron 1000 vial and Sustanon 250 ampoule.

• A reminder - Sustanon 250 contains arachis (peanut) oil so is not suitable for people with a nut allergy.

• For more information see Depo-Testosterone on Pharmac website

Questions

If you have any queries, please contact us at enquiry@pharmac.govt.nz

Please share this information

Please share this information with your colleagues and within your networks.

If you no longer wish to receive emails from the Pharmac Implementation Team, please send a reply email with UNSUBSCRIBE in the subject heading. Thank you.

Ngā mihi

David Hughes

Chief Medical Officer | Director Advice & Assessment

________________________________________________________________________________

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

DDI: +64 21 962 317 | P: +64 4 460 4990 |  www.pharmac.govt.nz